Editorial
|
|
|
|
|
Helping victims of drug-induced harms
|
|
|
|
Marketing Authorisations
|
|
|
|
|
Castleman's disease: good symptomatic efficacy in some patients
|
|
|
|
|
|
|
|
|
|
Effective but tricky to use
|
|
|
|
|
|
|
|
|
|
|
|
For some severely affected patients
|
|
|
|
Adverse Effects
|
|
|
|
|
Prescribers and pharmacists should be aware of the problem
|
|
|
|
|
|
|
|
|
|
Mostly in type 2 diabetes
|
|
|
|
|
|
|
|
|
|
Monitoring infusions is key
|
|
|
|
|
|
|
|
|
|
Unfavourable harm-benefit balance
|
|
|
|
|
|
|
|
|
|
An unexpected adverse effect
|
|
|
|
|
|
|
|
|
|
Visual disturbances are warning symptoms
|
|
|
|
|
|
|
|
|
|
ACE inhibitors are the most commonly implicated
|
|
|
|
|
|
|
|
|
|
Opioids can trigger angioedema
|
|
|
|
|
|
|
|
|
|
A combination that is best avoided
|
|
|
|
|
|
|
|
|
|
Bear in mind the risk of systemic absorption
|
|
|
|
|
|
|
|
|
|
Packaging needs improvement
|
|
|
|
|
|
Reviews
|
|
|
|
|
A summary of first-choice treatments
|
|
|
|
|
|
|
|
|
|
Improvements in quality of life
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Industry opposed the ban on 3 neonicotinoid pesticides in the EU
|
|
|
|
|
|